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Ifosfamide is a prodrug that requires bioactivation by cytochrome P450 for antitumour activity. Up to now, little is known, to what
extent in addition to the liver the ifosfamide metabolism may occur intratumorally. For this purpose, we investigated the expression
of CYP3A4, CYP2C9 and CYP2B6 in breast cancer tissue using Western Blotting. Ifosfamide turnover was determined by detection
of metabolites of the ifosfamide 4-hydroxylation and N-dechloroethylation in tumour microsomal incubations using HPLC/UV and
LC/MS. The results demonstrate that all mammary tumours (n¼11) reveal CYP3A4 expression; contents varied from 0.5 to
63pmolmgprotein
 1 . CYP2C9 (n¼9) was present in all tested breast tumour samples, too, while CYP2B6 (n¼10) protein could not be
detected. All measured breast cancer microsomes (n¼4) showed an ifosfamide N-dechloroethylation capacity in the range from
0.04 to 0.21pmolmin
 1mgprotein
 1 , while metabolites of the 4-hydroxylation could not be determined. In conclusion, the detected
presence of CYP3A4 and CYP2C9 in breast tumours offers the possibility of intratumoral turnover of ifosfamide. For the first time in
the literature, we could demonstrate a turnover of ifosfamide by microsomal preparations from human breast cancer tissue. A
calculated modulation of intratumoral ifosfamide turnover could considerably influence its therapeutic efficiency.
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Cytochrome P450 enzymes are of potential importance in the
aetiology and treatment of breast cancer due to their involvement
in the activation and/or degradation of carcinogens, steroid
hormones as well as bioactivation of some widely used cytostatic
prodrugs like oxazaphosphorines. The metabolic activation of
oxazaphosphorines is thought to take place primarily in the liver.
However, the 4-hydroxylation products of oxazaphosphorines are
characterised by a rapid half-life and their spontaneously
decomposed and tumourstatic active phosphoramide mustards
show a low membrane permeability (Lenssen and Hohorst, 1979;
Patterson and Murray, 2002). It is assumed that an intratumorally
occurring oxazaphosphorine bioactivation, in addition to the liver,
could be important in the realisation of their cytotoxic effects.
According to Patterson and Murray (2002), phenotyping of patient
tumours for CYPs 2B, 2C and 3A prior to oxazaphosphorine
therapy may help predict clinical outcome.
Ifosfamide, a member of the oxazaphosphorine class, requires
P450-mediated bioactivation via 4-hydroxylation to form cytotoxic
metabolites, whereas a CYP-dependent N-dechloroethylation
reaction produces inactive ifosfamide metabolites. Principal
catalysts of the hepatic ifosfamide 4-hydroxylation are CYP3A4
and CYP2C9 enzymes, while CYP3A4 and CYP2B6 have demon-
strated the major isoforms in the hepatic N-dechloroethylation
reaction (Chang et al, 1993, Roy et al, 1999a,b, Preiss et al, 2002).
In human breast tumours, CYP3A protein, the most interesting
with regard to ifosfamide metabolism, could be detected, but its
reported expression rate is highly variable and dependent on the
detection method used. In immunohistochemical investigations,
detected CYP3A in breast tumour tissue varied from 0 to 100%
(Forrester et al, 1990; Murray et al, 1993; Yokose et al, 1999). Using
Western Blotting methods, Chabot et al (1996) showed the
presence of CYP3A4 in all 10 tested breast cancer samples, while
Forrester et al (1990), Albin et al (1993) and Hellmold et al (1998)
described negative results. Reverse transcription–PCR analysis
demonstrated the presence of CYP3A4 mRNA in 15% (Huang et al,
1996) and 75% (Hellmold et al, 1998) of tested breast cancer
samples, respectively.
The situation with regard to CYP2C9 expression is similarly
contradictory. Detection rates of CYP2C protein by Western
Blotting varied from 0% (Albin et al, 1993) to 100% (Forrester et al,
1990), again, while reported rates using either anti-rat 2C-
antibodies (Forrester et al, 1990) or antibodies raised against
purified human CYP2C9 (recognising 2C8, 2C9, 2C18 and 2C19 on
Western Blotting) (Yokose et al, 1999) in immunohistochemistry
amounted to 33 and 39%, respectively. By RT–PCR analysis, a
CYP2C fragment could be detected in all tested tumour tissue
samples (Huang et al, 1996; Hellmold et al, 1998).
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sTwo investigations on CYP2B6 expression in breast cancer
demonstrated that CYP2B6 mRNA was expressed in breast
cancer samples (I `scan et al, 1998, Hellmold et al, 1998). No
data exist about the expression of the CYP2B6 protein in this
tumour.
Regardless of these contradictory results, fundamental condi-
tions for possible ifosfamide turnover seem to be present in human
breast cancer tissue. However, the identification of various CYP
mRNA and protein in tumours does not provide evidence of
enzyme activity. It is essential that if these tumoral CYP forms are
to be a focus for P450-directed prodrug development, then the
intrinsic activity of the isoforms identified must be demonstrated
(Patterson et al, 1999).
Therefore, we firstly, for our knowledge, investigated the
possibility of intratumoral ifosfamide turnover in human breast
cancer in vitro using microsomal preparations from breast cancer
tissue and highly sensitive HPLC/UV and LC/MS detection to
determine metabolites of ifosfamide bioactivation (4-hydroxyla-
tion) and N-dechloroethylation as well as Western Blotting to
detect the expression of CYP3A4, CYP2C9 and CYP2B6 in the
tumour samples.
MATERIAL AND METHODS
Chemicals
Ifosfamide and its metabolites were a gift from Asta Medica AG
(Frankfurt, Germany). Acrolein, mesna, chloroacetaldehyde, 2,4-
dinitrophenylhydrazine, glucose-6-phosphate and NADPH were
purchased from Sigma-Aldrich Chemie GmbH (Steinheim,
Germany). Glucose-6-phosphate dehydrogenase from yeast and
NADP were from Boehringer Mannheim GmbH (Mannheim,
Germany).
Anti-human P450 3A4 antibodies were purchased from
Oxford Biomedical Research, (Oxford, USA). Anti-human CYP3A5
(WB-3A5), anti-human CYP2C9 (WB-2C9) and anti-human
CYP2B6 (WB-2B6) Western Blotting kits as well as recombinant
human CYP3A4, CYP3A5, CYP3A7, CYP2C9*1, CYP2B6 and
human NADPH P450-reductase were purchased from Gentest
Corporation (Woburn, USA). ECL-reagents and ECL-hyperfilm
were from Amersham Buchler GmbH & Co KG (Braunschweig,
Germany).
Solvents were HPLC grade from JT Baker BV (Deventer,
Holland). All other chemicals not listed were purchased in the
highest purity available.
Patients
The study was approved by the Leipzig University Ethics
Committee, and written consent was obtained from each patient.
The investigation was carried out with 11 breast cancer patients
(aged 45–92 years). The tumoral tissue specimens removed at the
time of surgery were promptly trimmed of fat and connecting
tissues. A part of each tissue sample was reserved for histopatho-
logical examination and the remainder was rapidly frozen in liquid
nitrogen and stored at  701C.
Preparation of human breast cancer tissue microsomes
Frozen tissue was homogenised in phosphate buffer (pH 7.4, 1/15 M
potassium phosphate, 1mM EDTA), the homogenate centrifuged at
11000g and 21C for 30min and the resultant supernatant
subjected to centrifugation at 100000g and 21C for 60min. The
resulting microsomal pellet was resuspended in phosphate buffer
containing 0.25 M sucrose and stored at  701C until use. Protein
concentrations were measured according to the method of
Bradford (1976).
Immunoblotting and CYP isoenzyme quantitation
Immunochemical determination was performed using several
commercially available anti-human P450 3A4, 3A5, 2C9 and 2B6
antibodies and microsome preparations from human lymphoblas-
toid cell lines transfected with human P450 isoenzyme cDNA as
standards.
Briefly, microsomal proteins and standards were separated
electrophoretically on 12% resolving polyacrylamide mini-gels
using a Mini Protean II electrophoresis unit (Bio-Rad Laboratories
GmbH Mu ¨nchen, Germany) and then quantitatively transferred
onto nitrocellulose sheets (0.45mm). After blocking for 1h in TRIS-
buffered saline containing 5% (wv
 1) membrane blocking reagent,
the membranes were incubated in diluted primary antibody for
1h. The sheets were then incubated in diluted biotinylated
secondary antibody for 1h followed by incubation of the blots in
diluted streptavidin-horseradish-peroxidase for 20min. ECL-re-
agents and ECL-hyperfilm were used for detection. In the case of
CYP3A4, the calibration curve was calculated from five concentra-
tions of the relevant standard on each blot. The intensity of the
CYP3A4 staining was quantitated using a ScanJet 4c scanner
(Hewlett Packard) and the Sigma Gel software from Jandel
Scientific.
Microsomal incubations
Microsomal incubations from human breast cancer tissue samples
were prepared according to the method of Ruzicka and Ruenitz
(1992) with minor modifications. Mixtures contained per ml 1mg
microsomal protein, potassium phosphate buffer, pH 7.4, 40mmol,
potassium chloride 120mmol, magnesium chloride 5mmol, mesna
300mg, either 2mmol NADPH or NADP 0.4mmol, glucose-6-
phosphate 120mmol and glucose-6-phosphate dehydrogenase
0.6U.
After prewarming in a 371C shaking water bath for 10min in the
presence of the NADPH-generating system or NADPH, the
reaction was initiated by adding ifosfamide (dissolved in 1.15%
potassium chloride) in a final concentration of 500mgml
 1
(D2m M). The incubation time was 4h. All investigations included
control incubations without microsomes.
Aliquots of every sample were withdrawn at 0min (after 10min
preincubation) and 4h. The reaction was stopped by freezing in
liquid nitrogen and the samples were stored at  701C until use.
Ifosfamide 4-hydroxylation
The 4-hydroxylation of ifosfamide was measured using an HPLC/
UV method to quantify the liberated acrolein. After removal of
protein by addition of 200ml 5% ZnSO4 and 200ml 2.5% Ba(OH)2
ml
 1 and following centrifugation at 450g for 10min at 41C, 500ml
of solution was mixed with 100ml dinitrophenylhydrazine
(1.56mgml
 1 dissolved in 2 N HCl) and 100ml chloroacetaldehyde
and incubated for 10min at room temperature. After the
derivatisation and extraction with 2ml hexane, the aqueous phase
was submitted to solid phase extraction. The following conditions
were chosen for the chromatography: gradient – A: 20%
acetonitrile/20mM KH2PO4 0.1% H3PO4; B: 80% acetonitrile/
20mM KH2PO4 0.1% H3PO4; scheme: 0–10min A, 10–35min
A-B, 35–38min B-A, 38–60min A; flow 1mlmin
 1, column
Nucleosil 100 RP18 (5mm). Daily calibration curves were used. The
detection wavelength was 357nm. The detection limit was
approximately 20ngml
 1.
Ifosfamide N-dechloroethylation
The N-dechloroethylation of ifosfamide was measured using a
high-sensitive HPLC/MS method to quantify the liberated 2- and 3-
dechloroethylifosfamide.
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with 150ml 0.1 N NaOH. After double extraction with 2ml aliquots
of chloroform and evaporation with nitrogen, the residues were
resolved in 100ml 30% methanol/20mM ammonium acetate with
ketocyclophosphamide (1mg) as internal standard. Detection was
performed using an SSQ 7000 mass spectrometer (Finnigan), a
Consta Metric 4100 MS HPLC pump (TSP) and a Spectra System
AS 3000 autosampler (TSP) with an Ultrasep ES 100 Pharm
(SEPSERV) RP 18 (125mm 2mm; 5mm) column. The mobile
phase consisted of 20% methanol and 80% 20mM ammonium
acetate containing 1ml acetic acid per litre at a flow of
0.3mlmin
 1. The injection volume was 20ml. The mass spectro-
metry parameters were: 10V CID-positive ionisation, temperature
of capillary 2201C and a needle voltage of 4.5kV. We used SIM-
modes 199 and 275 for 2- and 3-dechloroethylifosfamide, and
ketocyclophosphamide. The detection limit was approximately
2ngml
 1.
RESULTS
Histopathological examination of breast tumour
specimens
Histopathological examination of breast tumours revealed an
infiltrating ductal carcinoma in eight cases (for example Figure 1),
in one case each a ductal/lobular and lobular carcinoma and one
ulcerated tumour. The histological gradation mainly showed grade
G2 and G3.
Western Blotting of CYP3A4, CYP2C9 and CYP2B6 in
breast cancer microsomes
CYP3A4 was detected in 11 out of 11 microsomal preparations. An
example of CYP3A4 quantitation using five concentrations of
recombinant CYP3A4 standard is given in Figure 2.
In contrast, none of the samples tested (10 out of 11) showed
CYP3A5 immunoreactivity (for example Figure 3).
All investigated breast tumours (nine out of 11) revealed low but
nevertheless positive staining of the CYP2C9 protein (Figure 4).
CYP2B6 protein was not expressed in any tumour sample tested
(10/11; for example Figure 5). The results of all CYP Western Blots
are summarised in Table 1.
Figure 1 Example of histopathological examination of breast tumour
specimen (invasive ductal carcinome, grade 2, breast cancer sample Eli 8).
1  Recombinant CYP3A4 standard 0.023 pmol
2  Recombinant CYP3A4 standard 0.053 pmol
3  Recombinant CYP3A4 standard 0.075 pmol
4  Recombinant CYP3A4 standard 0.113 pmol
5  Recombinant CYP3A4 standard0.263 pmol
6  Tumour T3 10 l
7  Tumour T3 10 l
8  Tumour T3  5 l
9  Tumour T3  5 l
10 Biotinylated molecular weight marker
1 2  3 4 5   6   7   8   9 10
14 400
31 000
21 500
45 000
66 200
97 400
Figure 2 Example of CYP3A4 Western blot (breast cancer sample T3).
All mammary tumours (n¼11) reveal CYP3A4 expression.
  1      2 3    4      5 6
1  Recombinant CYP3A5 standard 0.375 pmol
2  Recombinant CYP3A4 standard 0.375 pmol 
3  Biotinylated molecular weight marker 
4  Tumour T4 10 l 
5  Tumour T5 10 l 
6  Tumour T6 10 l
Figure 3 Anti-human CYP3A5 Western blot. None of the breast
samples tested (10 out of 11) showed CYP3A5 immunoreactivity.
123456789 1 0 1 1 1 2
66 200
1  Recombinant CYP2C9 standard 0.225 pmol
2  Recombinant CYP2C9 standard 0.225 pmol
3  Tumour T6 10 l
4  Tumour T4 10 l
5  Tumour T5  10 l
6  Tumour Eli4 10 l
7  Tumour Eli8 10 l
8  Tumour P2 10 l
9  Tumour T3 10 l
10  Tumour T2 10 l
11  Tumour P11 10 l
12 Biotinylated molecular weight marker 
45 000
31 000
Figure 4 Anti-human CYP2C9 Western blot. CYP2C9 was present in all
tested breast tumour samples (nine out of 11).
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Acrolein could not be detected in all tested breast cancer samples
T2, T3, T4 and Eli3.
Ifosfamide N-dechloroethylation
In a preliminary examination, we tested the direct addition of
NADPH to the microsomal incubations. No measurable ifosfamide
N-dechloroethylation activity could be detected in the tested four
breast cancer samples T3, E1, Eli4 and Eli3. Using the addition of
NADPH-generating system to the microsomal incubations, ifosfa-
mide N-dechloroethylation activity of the tested four breast cancer
samples T4, T5, T6 and Eli8, measured as sum from 2- and 3-
dechloroethylifosfamide, ranged from 0.04 to
0.21pmolmin
 1mgprotein
 1 (mean: 0.1270.07pmolmin
 1mgprotein
 1 ).
Ifosfamide N-dechloroethylation activities of the four tested
tumour samples T5, T6, P2 and P11 with the addition of NADPH-
generating systemþ5Uml
 1 P450-reductase were in the range
from 0.07 to 1.46pmolmin
 1mgprotein
 1 (Table 2). Owing to a very
limited quantity of tumoral microsomes, a parallel measurement of
basic ifosfamide N-dechloroethylation and with addition of P450-
reductase was practicable in two cases (T5, T6) only.
DISCUSSION
Investigation of the extrahepatic, especially intratumoral, presence,
function and regulation of cytochrome P450 has become a major
area of interest in recent years. P450 enzymes have been detected
in human breast cancers, but data are conflicting. Knowledge of
their capacity to bioactivate cytostatic prodrugs like oxazapho-
sphorines is very scant.
Therefore, we firstly investigated the possibility of ifosfamide
turnover in human breast cancer microsomes using highly
sensitive HPLC/UV and LC/MS detection methods to determine
ifosfamide metabolites and Western Blotting to detect the
expression of CYP3A4, CYP2C9 and CYP2B6 proteins in the
tumours.
Using a polyclonal anti-human CYP3A4 antibody (detecting
CYP34A, 3A5 and 3A7) and recombinant CYP3A4 as a standard,
we detected and quantified CYP3A by Western Blotting in all 11
tested breast cancer samples. The content of this isoform varied
from 0.5 to 63pmolmgprotein
 1 (19.9721.6pmolmgprotein
 1 ). Com-
paratively, the same antibody detected levels of CYP3A in female
liver microsomes, which has been demonstrated to be significantly
higher than in male samples, amounting to 141 and
69pmolmgprotein
 1 (median; P¼0.038, Mann–Whitney rank sum
test), respectively (Figure 6) (Schmidt et al, 2001). The use of a
CYP3A5-specific antibody allowed us to exclude the expression of
CYP3A5 in the tested tumours, but the involvement of CYP3A7
could not be further clarified because of the absence of a specific
anti-CYP3A7 antibody.
Using a monoclonal anti-human CYP3A4 antibody, Chabot et al
(1996) also showed the presence of CYP3A protein in all 10 tested
breast cancer samples. In the investigations of Chabot et al (1996),
tumour CYP3A4 levels were found to be more than 120-fold lower
than in corresponding liver samples. These relatively low tumoral
P450 levels could be explained by the fact that both our
investigation and the study of Chabot et al (1996) exclusively
used the microsomal fraction, in accordance with most groups
working in this area. However, tumour cells, in contrast to liver,
have a paucity of smooth endoplasmic reticulum and the usual
microsomal preparation may not be suitable in the case of tumour
tissue. Furthermore, tumoral P450 may not be exclusively located
in the smooth endoplasmic reticulum (Murray, 2000). Examination
1      2      3 4 5 6 7 8    9 
1    Recombinant CYP2B6 standard 0.35 pmol
2  Recombinant CYP2B6 standard 0.7 pmol
3  Tumour P2   10 l
4  Tumour P11 10 l
5  Tumour T4 10 l
6  Tumour T5 10 l
7  Tumour T6 10 l
8  Tumour Eli4 10 l
9  Biotinylated molecular weight marker
66 200
45 000 
Figure 5 Anti-human CYP2B6 Western blot. CYP2B6 protein could not
be detected in all tested breast tumours (10 out of 11).
Table 1 CYP3A4/5, CYP2C9 and CYP2B6 contents in breast cancer
samples
Tumour
sample
CYP3A4
(pmolmgprotein
 1 ) CYP3A5 CYP2C9 CYP2B6
T2 0.5   +  
T3 12   +  
T4 53   +  
T5 18   +  
T6 38   +  
E1 0.5 n.m. n.m. n.m.
Eli 3 6   n.m.  
Eli 4 15   +  
Eli 8 63   +  
P2 7   +  
P1 1 6   +  
n.m.¼not measured.
Table 2 Ifosfamide N-dechloroethylation activity (sum from 2- and 3-dechloroethylifosfamide) with addition of NADPH-generating system and NADPH-
generating system+P450-reductase
NADPH generating system NADPH generating system+P450-reductase
Tumour sample
N-dechloroethylation
(pmolmin
 1mgprotein
 1 ) Tumour sample
N-dechloroethylation
(pmolmin
 1mgprotein
 1 )
T4 0.04
T5 0.21 T5 0.07
T6 0.12 T6 1.46
Eli8 0.11
P2 0.25
P11 0.07
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should be included in future determination of tumour CYP
content.
In this study, firstly using a specific anti-human CYP2C9
antibody in Western Blotting, which does not crossreact with other
CYP2C-members (CYP2C8, CYP2C18, CYP2C19), we could also
show weak expression of CYP2C9 protein in all human breast
tumours tested. In contrast, Albin et al (1993) and Hellmold et al
(1998), using anti-human CYP2C8-10 and anti-human CYP2C10,
respectively, did not detect CYP2C protein in breast cancer tissue
by this method.
Additionally, CYP2B6 detection with an antibody strongly
reacting with human cDNA-expressed CYP2B6 (detection limit
approximately 0.2pmol) showed no positive immunostaining in all
tested breast tumour samples (10 out of 11). Assuming a
proportion of CYP2B6 similar to the human liver, where in our
previous investigation (Preiss et al, 2002) the percentage of this
P450 isoform amounted to only 2.6% of total P450, the sensitivity
of the used Western Blotting is not enough to detect the minor
isoenzyme CYP2B6.
However, our results demonstrate that the investigated breast
cancer samples express at least two members of the CYP family,
raising the possibility that CYP3A4- and CYP2C9-catalysed
metabolism in tumour tissue could result in local bioactivation
and/or deactivating N-dechloroethylation of ifosfamide.
In fact, all measured breast cancer samples (n¼4) showed
minimal ifosfamide N-dechloroethylation activities in vitro
(0.1270.07pmolmin
 1mgprotein
 1 ), whereas metabolites of ifosfa-
mide 4-hydroxylation (n¼4) could not be detected. However, it
should be taken into account that in our investigations the
detection limit of the ifosfamide 4-hydroxylation reaction was 10-
fold higher than that of ifosfamide N-dechloroethylation reaction
(20 vs 2ngml
 1). In comparison, our previous investigations on 10
human female liver samples showed activities of
132757pmolmin
 1mg
 1 protein for ifosfamide N-dechloroethy-
lation and 11437208pmolmin
 1mg
 1 protein for ifosfamide 4-
hydroxylation.
Only a limited number of comparable investigations exist that
analysed the metabolic capacity of human breast tumour tissue
such as the both CYP1A1-mediated ethoxyresorufin O-deethylase
(I `scan et al, 1999) and aryl hydrocarbon hydroxylase activities
(Pyykko et al, 1991).
Senler et al (1985) found the average cyclohexane (as a substrate
for several forms of cytochrome P450) hydroxylase activity in 139
human breast tumour microsome preparations in the range of
those observed for untreated rabbit liver microsomes.
In contrast, the catalytic activity of the CYP2A6-specific
coumarin hydroxylation varied in four measured breast cancer
microsomes between 1.6 and 4pmolmin
 1mgprotein
 1 , whereas in
human liver microsomes this activity was approximately
24nmolmin
 1mgprotein
 1 (Hellmold et al, 1998). Thus, Hellmold
et al (1998) found a similar breast tumour/liver activity ratio for
coumarin hydroxylation as we did for ifosfamide N-dechloroethy-
lation.
The NADPH cytochrome P450-reductase is an obligatory and
often rate-limiting component of microsomal P450-dependent
activities. P450-reductase and CYP2B6 gene cotransferred into
gliosarcoma cells significantly increased the cyclophosphamide
and ifosfamide activation (Jounaidi et al, 1998). Sequeira and
Strobel (1996) demonstrated on rat brain microsomes an increased
imipramine metabolism by addition of exogenous purified P450-
reductase. Therefore, to test whether the measured minimal
ifosfamide N-dechloroethylation activity could be improved by
addition of this cofactor, P450-reductase (5unitsml
 1) was added.
Owing to the very limited quantities of breast tumour microsomes,
a parallel measurement of basic ifosfamide N-dechloroethylation
and ifosfamide N-dechloroethylation after addition of P450-
reductase was practicable in two cases only. Our results demon-
strated an enhancement of ifosfamide N-dechloroethylation
activity in the tumour microsomal preparation T6, while with
the addition of P450-reductase this activity was decreased in
tumour microsomes T5. Possibly, this discrepancy can be
explained by the use of different lots of P450-reductase. However,
further investigations are needed to clarify the importance of this
cofactor in tumoral CYP-mediated metabolism.
In conclusion, the presence of two important ifosfamide
catalysts CYP3A4 and CYP2C9 in breast tumours suggests that
its local turnover could be of importance in cancer therapy. We
succeeded in detecting minimal ifosfamide N-dechloroethylation
activities (0.1270.07pmolmin
 1mgprotein
 1 ) using LC/MS in all
measured breast cancer microsomes, while the HPLC/UV method
developed was not sensitive enough to detect metabolites of the
ifosfamide 4-hydroxylation. This is the first demonstration of the
ifosfamide turnover by microsomal preparations from human
breast cancer tissue. Finally, expression of xenobiotic metabolising
enzymes with actual basic metabolic capacity in breast tumours
has been identified as a potentially important factor in the
modulation of the, so far underestimated, intratumoral CYP-
mediated prodrug activation.
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